Europe & Central Asia | Immunization, measles (% of children ages 12-23 months)
Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine. Development relevance: Immunization is one of the most cost-effective public health interventions, and ??is an essential component for reducing under-five mortality. Immunization coverage estimates are used to monitor coverage of immunization services and to guide disease eradication and elimination efforts. Limitations and exceptions: In many developing countries a lack of precise information on the size of the cohort of one-year-old children makes immunization coverage difficult to estimate from program statistics. Statistical concept and methodology: Governments in developing countries usually finance immunization against measles and diphtheria, pertussis (whooping cough), and tetanus (DTP) as part of the basic public health package. The data shown here are based on an assessment of national immunization coverage rates by the WHO and UNICEF. The assessment considered both administrative data from service providers and household survey data on children's immunization histories. Based on the data available, consideration of potential biases, and contributions of local experts, the most likely true level of immunization coverage was determined for each year. Notes on regional and global aggregates: When the vaccine is not introduced in a national immunization schedule, the missing value is assumed zero (or close to zero) in the relevant groups' averages.
Publisher
The World Bank
Origin
Europe & Central Asia
Records
63
Source
Europe & Central Asia | Immunization, measles (% of children ages 12-23 months)
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
81.26367033 1992
82.71154237 1993
82.70090433 1994
83.90489611 1995
86.20057989 1996
88.08474245 1997
88.1325246 1998
89.54375807 1999
90.78828959 2000
91.64900021 2001
90.89483328 2002
90.39301004 2003
91.53348067 2004
93.05148768 2005
94.37208935 2006
94.67615969 2007
94.75675092 2008
93.68651949 2009
93.39389488 2010
94.23080403 2011
94.76102072 2012
95.02141231 2013
93.53759411 2014
93.80764986 2015
93.30443407 2016
95.1518007 2017
95.20182272 2018
95.6253065 2019
93.73662053 2020
93.94210325 2021
93.32342484 2022
Europe & Central Asia | Immunization, measles (% of children ages 12-23 months)
Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine. Development relevance: Immunization is one of the most cost-effective public health interventions, and ??is an essential component for reducing under-five mortality. Immunization coverage estimates are used to monitor coverage of immunization services and to guide disease eradication and elimination efforts. Limitations and exceptions: In many developing countries a lack of precise information on the size of the cohort of one-year-old children makes immunization coverage difficult to estimate from program statistics. Statistical concept and methodology: Governments in developing countries usually finance immunization against measles and diphtheria, pertussis (whooping cough), and tetanus (DTP) as part of the basic public health package. The data shown here are based on an assessment of national immunization coverage rates by the WHO and UNICEF. The assessment considered both administrative data from service providers and household survey data on children's immunization histories. Based on the data available, consideration of potential biases, and contributions of local experts, the most likely true level of immunization coverage was determined for each year. Notes on regional and global aggregates: When the vaccine is not introduced in a national immunization schedule, the missing value is assumed zero (or close to zero) in the relevant groups' averages.
Publisher
The World Bank
Origin
Europe & Central Asia
Records
63
Source